{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:19:40Z","timestamp":1777421980588,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40263-017-0437-9","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T10:14:43Z","timestamp":1498644883000},"page":"797-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study"],"prefix":"10.1007","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct00488319","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Srihari","family":"Gopal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanne","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Nuamah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Copenhaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaskaran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"issue":"8","key":"437_CR1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4065\/80.8.1050","volume":"80","author":"ME Molitch","year":"2005","unstructured":"Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050\u20137.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"437_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1185\/030079903125002865","volume":"20","author":"M Hummer","year":"2004","unstructured":"Hummer M, Huber J. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin. 2004;20(2):189\u201397.","journal-title":"Curr Med Res Opin."},{"issue":"5","key":"437_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/syn.890010503","volume":"1","author":"P Seeman","year":"1987","unstructured":"Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, et al. Human brain dopamine receptors in children and aging adults. Synapse. 1987;1(5):399\u2013404.","journal-title":"Synapse."},{"issue":"Suppl 4","key":"437_CR4","first-page":"26","volume":"69","author":"CU Correll","year":"2008","unstructured":"Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):26\u201336.","journal-title":"J Clin Psychiatry."},{"issue":"12","key":"437_CR5","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1517\/14656566.9.12.2053","volume":"9","author":"V Madaan","year":"2008","unstructured":"Madaan V, Dvir Y, Wilson DR. Child and adolescent schizophrenia: pharmacological approaches. Expert Opin Pharmacother. 2008;9(12):2053\u201368.","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"437_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000284360","volume":"73","author":"L Saranac","year":"2010","unstructured":"Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, Miljkovic P. Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr. 2010;73(3):187\u201392.","journal-title":"Horm Res Paediatr."},{"issue":"Suppl 1","key":"437_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","volume":"28","author":"AJ Cutler","year":"2003","unstructured":"Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology. 2003;28(Suppl 1):69\u201382.","journal-title":"Psychoneuroendocrinology."},{"issue":"6","key":"437_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.psyneuen.2008.02.008","volume":"33","author":"H Knegtering","year":"2008","unstructured":"Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008;33(6):711\u20137.","journal-title":"Psychoneuroendocrinology."},{"issue":"4","key":"437_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/cap.2008.0120","volume":"19","author":"Y Roke","year":"2009","unstructured":"Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol. 2009;19(4):403\u201314.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"9896","key":"437_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet."},{"key":"437_CR11","doi-asserted-by":"publisher","first-page":"502697","DOI":"10.1155\/2013\/502697","volume":"2013","author":"SI Bargiota","year":"2013","unstructured":"Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women\u2019s menstruation. Schizophr Res Treat. 2013;2013:502697. doi:10.1155\/2013\/502697 \n                           (Epub 2013 Dec 24).","journal-title":"Schizophr Res Treat."},{"issue":"2","key":"437_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1192\/bjpo.bp.115.001248","volume":"1","author":"G Raghuthaman","year":"2015","unstructured":"Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. B J Psych Open. 2015;1(2):172\u20137. doi:10.1192\/bjpo.bp.115.001248.","journal-title":"B J Psych Open."},{"issue":"12","key":"437_CR13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","volume":"70","author":"J Singh","year":"2011","unstructured":"Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry. 2011;70(12):1179\u201387.","journal-title":"Biol Psychiatry."},{"issue":"3","key":"437_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1089\/cap.2006.16.260","volume":"16","author":"M Reyes","year":"2006","unstructured":"Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol. 2006;16(3):260\u201372.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"3","key":"437_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/cap.2006.16.317","volume":"16","author":"J Staller","year":"2006","unstructured":"Staller J. The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol. 2006;16(3):317\u201326.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"7","key":"437_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1089\/cap.2014.0130","volume":"25","author":"A Savitz","year":"2015","unstructured":"Savitz A, Lane R, Nuamah I, Singh J, Hough D, Gopal S. Long-term safety of paliperidone extended release in adolescents with schizophrenia: an open label, flexible dose study. J Child Adolesc Psychopharmacol. 2015;25(7):548\u201357.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"235","key":"437_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/adc.44.235.291","volume":"44","author":"WA Marshall","year":"1969","unstructured":"Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44(235):291\u2013303.","journal-title":"Arch Dis Child."},{"issue":"239","key":"437_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/adc.45.239.13","volume":"45","author":"WA Marshall","year":"1970","unstructured":"Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13\u201323.","journal-title":"Arch Dis Child."},{"issue":"11","key":"437_CR19","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","volume":"165","author":"L Sikich","year":"2008","unstructured":"Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165(11):1420\u201331.","journal-title":"Am J Psychiatry."},{"issue":"9","key":"437_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40263-014-0184-0","volume":"28","author":"E Offidani","year":"2014","unstructured":"Offidani E, Fava GA, Sonino N. Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs. CNS Drugs. 2014;28(9):769\u201374.","journal-title":"CNS Drugs."},{"issue":"1","key":"437_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145711001076","volume":"15","author":"WW Fleischhacker","year":"2012","unstructured":"Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107\u201318.","journal-title":"Int J Neuropsychopharmacol."},{"issue":"1","key":"437_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","volume":"24","author":"R Knegtering","year":"2004","unstructured":"Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol. 2004;24(1):56\u201361.","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"437_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/JCP.0b013e3182199bcc","volume":"31","author":"P Malik","year":"2011","unstructured":"Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW, EUFEST Study Group. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011;31(3):274\u201380.","journal-title":"J Clin Psychopharmacol."},{"issue":"12","key":"437_CR24","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1017\/S0033291713000226","volume":"43","author":"A Riecher-R\u00f6ssler","year":"2013","unstructured":"Riecher-R\u00f6ssler A, Rybakowski JK, Pflueger MO, Beyrau R, Kahn RS, Malik P, Fleischhacker WW, EUFEST Study Group. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol Med. 2013;43(12):2571\u201382.","journal-title":"Psychol Med."},{"issue":"1","key":"437_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pnpbp.2006.07.006","volume":"31","author":"T Paparrigopoulos","year":"2007","unstructured":"Paparrigopoulos T, Liappas J, Tzavellas E, Mourikis I, Soldatos C. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):92\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"2","key":"437_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","volume":"28","author":"R Emsley","year":"2008","unstructured":"Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210\u20133.","journal-title":"J Clin Psychopharmacol."},{"issue":"Suppl 2","key":"437_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28(Suppl 2):69\u201382.","journal-title":"Psychoneuroendocrinology."},{"issue":"5","key":"437_CR28","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4088\/JCP.v69n0515","volume":"69","author":"HY Meltzer","year":"2008","unstructured":"Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69(5):817\u201329.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"437_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/104454602760219126","volume":"12","author":"CL Alfaro","year":"2002","unstructured":"Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002;12(2):83\u201391.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"11","key":"437_CR30","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64(11):1362\u20139.","journal-title":"J Clin Psychiatry."},{"issue":"20","key":"437_CR31","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314.","journal-title":"Drugs."},{"issue":"2","key":"437_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/JCP.0b013e31820e4832","volume":"31","author":"T Veselinovic","year":"2011","unstructured":"Veselinovic T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gr\u00fcnder G. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011;31(2):214\u201320.","journal-title":"J Clin Psychopharmacol."},{"issue":"Suppl 2","key":"437_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28(Suppl 2):55\u201368.","journal-title":"Psychoneuroendocrinology."},{"issue":"3","key":"437_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.pnpbp.2010.02.014","volume":"34","author":"N Yasui-Furukori","year":"2010","unstructured":"Yasui-Furukori N, Saito M, Nakagami T, Sugawara N, Sato Y, Tsuchimine S, et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):537\u201340.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"2","key":"437_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R, O\u2019Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22(2):109\u201314.","journal-title":"J Clin Psychopharmacol."},{"issue":"12","key":"437_CR36","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1210\/jc.2001-011943","volume":"87","author":"TP Smith","year":"2002","unstructured":"Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab. 2002;87(12):5410\u20135.","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"437_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","volume":"45","author":"CU Correll","year":"2006","unstructured":"Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771\u201391.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"2","key":"437_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1210\/jcem-48-2-338","volume":"48","author":"FQ Nuttall","year":"1979","unstructured":"Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab. 1979;48(2):338\u201340.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"437_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0002-9378(73)90732-1","volume":"117","author":"F Pettersson","year":"1973","unstructured":"Pettersson F, Fries H, Nillius SJ. Epidemiology of secondary amenorrhea. I. Incidence and prevalence rates. Am J Obstet Gynecol. 1973;117(1):80\u20136.","journal-title":"Am J Obstet Gynecol."},{"issue":"4","key":"437_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1542\/peds.99.4.505","volume":"99","author":"ME Herman-Giddens","year":"1997","unstructured":"Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings Network. Pediatrics. 1997;99(4):505\u201312.","journal-title":"Pediatrics."},{"issue":"5","key":"437_CR41","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1542\/peds.110.5.911","volume":"110","author":"SS Sun","year":"2002","unstructured":"Sun SS, Schubert CM, Chumlea WC, Roche AF, Kulin HE, Lee PA, et al. National estimates of the timing of sexual maturation and racial differences among US children. Pediatrics. 2002;110(5):911\u20139.","journal-title":"Pediatrics."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-017-0437-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0437-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0437-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:50:59Z","timestamp":1628617859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-017-0437-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0437-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]},"assertion":[{"value":"28 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study and writing\/editorial support for this paper was funded by Janssen Research & Development, LLC, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MC is a contract employee of Janssen Research & Development, LLC, NJ, USA. SG, RL, IN, JS, DH, MB, and AS are employees of Janssen Research & Development, LLC, or of Janssen Pharmaceutical KK, and hold stock in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The Independent Ethics Committee or Institutional Review Board at each study site approved the protocol, and the study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, consistent with Good Clinical Practices, and applicable regulatory requirements. All patients provided assent, and parents or guardians of these adolescent patients provided written informed consent before entering the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standards"}}]}}